Ovarian Cancer: PARP Inhibitor Eligibility

Written by: Martina Fraga, PharmD Download Here Description: The purpose of this PQI is to highlight effective practices to ensure ovarian cancer patients are identified, tested, tracked, and offered a PARP inhibitor when appropriate. Background: In gynecologic cancer...

Chronic Lymphocytic Leukemia with Del17p

Written by Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates Download Here Description: Chronic Lymphocytic Leukemia (CLL) diagnosis with the chromosomal abnormality of 17p Deletion is associated with a poor prognosis.  The 17p deletion is found 3‐10%...